Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody–Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas

医学 癌症研究 药品 结合 抗体 药理学 免疫学 数学分析 数学
作者
Niccolò G. Santin,Namrata Sethi,Stefania Bellone,Cem Demirkiran,Victoria M. Ettorre,Michelle P. Greenman,Blair C. McNamara,Natália Buza,Tobias M.P. Hartwich,Luca Palmieri,Domenica Lorusso,Alessandro Davide Santin
出处
期刊:Cancer research communications [American Association for Cancer Research]
卷期号:5 (9): 1611-1620 被引量:3
标识
DOI:10.1158/2767-9764.crc-25-0251
摘要

Datopotamab deruxtecan (Dato-DXd) is a novel antibody-drug conjugate (ADC) targeting trophoblast antigen-2 (TROP2), a cell surface glycoprotein highly expressed in many epithelial tumors, to deliver DXd, a potent topoisomerase I inhibitor. We evaluated TROP2 expression in primary endometrial cancer cell lines and the activity of Dato-DXd against endometrial cancer cell lines with different TROP2 expression in vitro and in vivo. TROP2 expression was assessed in nine primary tumor cell lines by flow cytometry. Cell viability after exposure to Dato-DXd was evaluated using flow cytometry-based assays to calculate the IC50. Bystander effect assay assessed the viability of TROP2-negative cells when cocultured with high TROP2-expressing cells. Fluorescent anti-phosphorylated histone H2AX antibody was used to demonstrate double-strand DNA breaks. Antibody-dependent cell cytotoxicity was tested in vitro using 4-hour chromium release assays. In vivo activity of Dato-DXd was evaluated against TROP2-positive endometrial cancer xenografts. A total of 78% (seven of nine) of the primary endometrial cancer cell lines expressed TROP2. Endometrial cancer cell lines expressing TROP2 were significantly more sensitive to Dato-DXd compared with control ADC. Dato-DXd-exposed, TROP2-positive endometrial cancer demonstrated increased double-strand DNA breaks compared with non-binding conjugate exposure. Dato-DXd mediated antibody-dependent cell cytotoxicity against TROP2-positive cell lines and induced significant bystander killing of TROP2-negative tumors when admixed with TROP2-positive tumors. In vivo, injection of Dato-DXd was well tolerated and demonstrated impressive tumor growth inhibition against chemotherapy-resistant poorly differentiated endometrial cancer xenografts (P < 0.0001). In conclusion, Dato-DXd is a novel ADC with remarkable preclinical activity against poorly differentiated endometrial cancer cell lines overexpressing TROP2. Clinical trials with Dato-DXd in patients with recurrent endometrial cancer are warranted. SIGNIFICANCE: Targeted treatment of aggressive forms of endometrial cancer using the biomarker TROP2 is a significant opportunity for the development of treatments when patients are resistant to other lines of treatment. Here, we present data showing preclinical evidence of effectiveness of this biomarker-targeted therapy in endometrial cancer.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
LI完成签到,获得积分10
刚刚
香蕉觅云的应助被RAIN采纳,获得10
1秒前
1秒前
犹豫的稀完成签到,获得积分10
1秒前
Daniel完成签到,获得积分10
2秒前
跳跃芷蕊完成签到,获得积分10
2秒前
情怀的应助被汉堡大王采纳,获得10
2秒前
3秒前
3秒前
小慈完成签到,获得积分10
3秒前
3秒前
adogi完成签到 ,获得积分20
3秒前
wyb完成签到,获得积分10
3秒前
科研民工完成签到,获得积分10
3秒前
整齐惋庭完成签到,获得积分10
3秒前
3秒前
4秒前
感性的楷瑞完成签到,获得积分10
4秒前
这朵蘑菇完成签到,获得积分10
4秒前
zz完成签到 ,获得积分10
4秒前
成就歌曲完成签到,获得积分10
4秒前
慕青的应助被tuimao采纳,获得10
5秒前
gcl发布了新的文献求助10
5秒前
5秒前
小王完成签到,获得积分10
5秒前
橘子海完成签到,获得积分10
5秒前
王珑完成签到 ,获得积分10
6秒前
YAOYAO完成签到,获得积分0
6秒前
曹广秀完成签到,获得积分10
6秒前
悲伤的茄子完成签到,获得积分10
6秒前
铁盐君完成签到,获得积分10
6秒前
海的呼唤完成签到,获得积分10
7秒前
西西完成签到,获得积分10
7秒前
WDD完成签到,获得积分10
7秒前
烽火残心完成签到 ,获得积分10
7秒前
Lili发布了新的文献求助30
7秒前
eternal_dreams完成签到 ,获得积分10
8秒前
羊羊完成签到,获得积分10
8秒前
钟贵泉完成签到,获得积分10
8秒前
Fan宝儿完成签到,获得积分10
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8173463
求助须知:如何正确求助?哪些是违规求助? 9565690
关于积分的说明 21781315
捐赠科研通 7767647
什么是DOI,文献DOI怎么找? 3431597
关于科研通互助平台的介绍 2555855
邀请新用户注册赠送积分活动 2476808